Noteworthy Short Interest Filing: Can Amarin Corporation Plc Ads (NASDAQ:AMRN)’s Tomorrow Be Different? The Stock Had Decline in Shorts

November 24, 2016 - By Marguerite Chambers   ·   0 Comments

Noteworthy Short Interest Filing: Can Amarin Corporation Plc Ads (NASDAQ:AMRN)’s Tomorrow Be Different? The Stock Had Decline in Shorts

The stock of Amarin Corporation Plc Ads (NASDAQ:AMRN) registered a decrease of 1.74% in short interest. AMRN’s total short interest was 5.64M shares in November as published by FINRA. Its down 1.74% from 5.74M shares, reported previously. With 3.57 million shares average volume, it will take short sellers 2 days to cover their AMRN’s short positions. The short interest to Amarin Corporation Plc Ads’s float is 3.09%. The stock increased 2.37% or $0.08 on November 23, hitting $3.46. About 1.89M shares traded hands. Amarin Corporation plc (ADR) (NASDAQ:AMRN) has risen 84.04% since April 22, 2016 and is uptrending. It has outperformed by 78.63% the S&P500.

Amarin Corporation plc is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The company has a market cap of $909.81 million. The Company’s lead product, Vascepa capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. The Firm operates in the business segment of development and commercialization of Vascepa.

Insitutional Activity: The institutional sentiment increased to 2.12 in 2016 Q2. Its up 1.08, from 1.04 in 2016Q1. The ratio improved, as 9 funds sold all Amarin Corporation plc (ADR) shares owned while 17 reduced positions. 7 funds bought stakes while 20 increased positions. They now own 30.07 million shares or 19.93% less from 37.56 million shares in 2016Q1.
California Employees Retirement has 470,500 shares for 0% of their US portfolio. Moreover, Next Grp Incorporated has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 500 shares. Bankshares Of America De last reported 82,669 shares in the company. Proshare Advisors Llc reported 132,338 shares or 0% of all its holdings. The New Jersey-based State Of New Jersey Common Pension Fund D has invested 0% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Broadfin Capital Limited Co has invested 0.98% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Loring Wolcott And Coolidge Fiduciary Llp Ma accumulated 13,325 shares or 0% of the stock. The Massachusetts-based Fmr Lc has invested 0% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Oracle Mngmt last reported 5.69M shares in the company. Citigroup Inc holds 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 23,207 shares. Vsr Fincl Ser has 22,200 shares for 0.01% of their US portfolio. Pura Vida Invests Limited Com has invested 1% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Blackrock Fund Advsr last reported 0% of its portfolio in the stock. Moreover, Timber Hill Ltd Limited Liability Company has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 53,504 shares. Carl Domino Inc holds 98,000 shares or 0.2% of its portfolio.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) Ratings Coverage

Out of 3 analysts covering Amarin Corp (NASDAQ:AMRN), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Amarin Corp has been the topic of 3 analyst reports since May 12, 2016 according to StockzIntelligence Inc. The rating was initiated by Jefferies with “Buy” on Thursday, May 12. Citigroup initiated Amarin Corporation plc (ADR) (NASDAQ:AMRN) on Wednesday, October 19 with “Buy” rating. Cantor Fitzgerald initiated Amarin Corporation plc (ADR) (NASDAQ:AMRN) rating on Wednesday, October 5. Cantor Fitzgerald has “Buy” rating and $6 price target.

AMRN Company Profile

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Firm operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Firm markets Vascepa in the United States through its sales force of approximately 150 sales professionals, including sales representatives and their managers.

Another recent and important Amarin Corporation plc (ADR) (NASDAQ:AMRN) news was published by Fool.com which published an article titled: “Why Amarin Corporation plc (ADR) is Moving Higher Today” on August 07, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>